Gossamer Bio Enters Into Securities Purchase Agreement For Up to $250M Structured Private Placement

– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH –

– Potential for Up to an Additional $100 Million Upon FDA Approval of Seralutinib –

– Financing Includes Participation from Existing Shareholders and Leading Healthcare Investors –